{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:51:32Z","timestamp":1793267492559,"version":"4.5.0"},"reference-count":67,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Antimicrobial resistance is a major public health problem in the US. Estimating national rates of antimicrobial-resistant infections commonly associated with health care can aid in targeted public health efforts.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To determine the national incidence rates of 6 pathogens over time: methicillin-resistant\n Staphylococcus aureus<\/jats:italic>\n (MRSA), vancomycin-resistant\n Enterococcus<\/jats:italic>\n spp (VRE), extended-spectrum cephalosporin-resistant\n Escherichia coli<\/jats:italic>\n and\n Klebsiella<\/jats:italic>\n spp (excluding\n Klebsiella aerogenes)<\/jats:italic>\n (ESCR-EK), carbapenem-resistant\n Enterobacterales<\/jats:italic>\n (CRE), carbapenem-resistant\n Acinetobacter<\/jats:italic>\n spp (CRAsp), and multidrug-resistant (MDR)\n Pseudomonas aeruginosa<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used data from 2012 to 2022 on inpatient hospitalizations, clinical cultures, and facility-level characteristics. Hospital-months were included in the dynamic cohort if the hospital reported at least 1 culture with microbial growth accompanied by antimicrobial susceptibility testing (AST) results in the month. Data from the PINC-AI and Becton Dickinson Insights databases were used, and cases were defined as incident nonsurveillance cultures yielding an organism of interest with sufficient AST results for a phenotype of interest. Data were collected from January 2012 to December 2022 and analyzed from April 2023 to June 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Inpatient hospitalizations with a discharge date in an included hospital month.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n National annual antimicrobial-resistant cases per 10\u202f000 hospitalizations were obtained using weights based on facility-level characteristics. Cases were defined as community-onset if collected on or before day 3 of hospitalization and hospital-onset if obtained on day 4 or later.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n This study cohort included 332 to 606 hospitals per year between 2012 to 2022 and 7\u202f158\u202f139 cultures. Antimicrobial-resistant pathogens accounted for an estimated 569\u202f749 (95% CI, 475\u202f949-663\u202f548) cases and 179.6 (95% CI, 163.1-196.1) cases per 10\u202f000 hospitalizations in 2022. Of these cases, 77% (437\u202f657; 95% CI, 364\u202f529-510\u202f785) were community-onset and 23% (132 092; 95% CI, 108\u202f241-155\u202f943) were hospital-onset. MRSA (44% [251\u202f854; 95% CI, 209\u202f558-294\u202f150]) and ESCR-EK (35% [200\u202f884; 95% CI, 163\u202f692-238\u202f077]) made up the largest proportions of total infections in 2022, respectively. Rates of hospital-onset MRSA, VRE, CRE, CRAsp, and MDR\n P aeruginosa<\/jats:italic>\n had periods of decline from 2012 to 2019; however, all pathogens experienced an increase in hospital-onset rates in 2020 and 2021. Community-onset ESCR-EK rates increased from 2012 to 2022, while community-onset rates of MRSA, VRE, and MDR\n P aeruginosa<\/jats:italic>\n declined.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n While antimicrobial resistance rates have experienced uneven declines in the US from 2012 to 2022, the burden of resistance remains substantial. These findings suggest that more effective strategies to reduce antimicrobial resistance are needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.62059","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:31:35Z","timestamp":1741951895000},"page":"e2462059","source":"Crossref","is-referenced-by-count":44,"title":["Antimicrobial-Resistant Infections in Hospitalized Patients"],"prefix":"10.1001","volume":"8","author":[{"given":"Hannah","family":"Wolford","sequence":"first","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Baggs","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Hatfield","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Maillis","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatunde","family":"Olubajo","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bishop","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Ferretti","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Craig","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley S.","family":"Magill","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Clifford","family":"McDonald","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.","family":"Sievert","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroya","family":"Spalding Walters","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Jernigan","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Lutgring","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujan C.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"14","key":"zoi241727r1","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in US hospitalized patients, 2012-2017.","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"issue":"10325","key":"zoi241727r2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"zoi241727r6","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"6","key":"zoi241727r8","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03129-23","article-title":"Real-world in vitro activity of newer antibiotics against Enterobacterales and Pseudomonas aeruginosa, including carbapenem-non-susceptible and multidrug-resistant isolates: a multicenter analysis.","volume":"11","author":"Riccobene","year":"2023","journal-title":"Microbiol Spectr"},{"key":"zoi241727r9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijid.2022.03.052","article-title":"Regional differences in antibiotic-resistant enterobacterales urine isolates in the United States: 2018-2020.","volume":"119","author":"Aronin","year":"2022","journal-title":"Int J Infect Dis"},{"key":"zoi241727r10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijid.2019.06.017","article-title":"National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States.","volume":"85","author":"Gupta","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"1","key":"zoi241727r11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s12879-019-4387-3","article-title":"Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013-2017.","volume":"19","author":"Gupta","year":"2019","journal-title":"BMC Infect Dis"},{"key":"zoi241727r15","doi-asserted-by":"publisher","DOI":"10.5888\/pcd13.150480","article-title":"A Methodological approach to small area estimation for the behavioral risk factor surveillance system.","volume":"13","author":"Pierannunzi","year":"2016","journal-title":"Prev Chronic Dis"},{"issue":"6","key":"zoi241727r16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/aje\/kwv080","article-title":"Health estimates using survey raked-weighting techniques in an Australian population health surveillance system.","volume":"182","author":"Dal Grande","year":"2015","journal-title":"Am J Epidemiol"},{"issue":"9","key":"zoi241727r17","first-page":"1","article-title":"Surveillance for certain health behaviors among states and selected local areas\u2013Behavioral Risk Factor Surveillance System, United States, 2011.","volume":"63","author":"Xu","year":"2014","journal-title":"MMWR Surveill Summ"},{"issue":"4","key":"zoi241727r18","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.apmr.2014.09.025","article-title":"A validation study for using iterative proportional fitting to weight the Traumatic Brain Injury Model Systems National Database: an NIDRR-sponsored study.","volume":"96","author":"Pretz","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"issue":"10","key":"zoi241727r20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1093\/cid\/ciab688","article-title":"The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections.","volume":"74","author":"Baker","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi241727r21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1017\/ice.2021.362","article-title":"The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: a summary of data reported to the National Healthcare Safety Network.","volume":"43","author":"Weiner-Lastinger","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"key":"zoi241727r22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.2073","article-title":"National trends in the rates of drug-resistant bacteria commonly associated with healthcare in US acute care hospitals, 2019-2021.","volume":"10","author":"Baggs","year":"2455","journal-title":"Open Forum Infect Dis"},{"key":"zoi241727r24","doi-asserted-by":"publisher","first-page":"S294","DOI":"10.1093\/cid\/ciac517","article-title":"Antibiotic-resistant infections among inpatients with coronavirus disease 2019 (COVID-19) in US hospitals.","volume":"75","author":"Baggs","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"12","key":"zoi241727r25","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jhm.12955","article-title":"Declines in the utilization of hospital-based care during COVID-19 pandemic.","volume":"17","author":"Kazakova","year":"2022","journal-title":"J Hosp Med"},{"key":"zoi241727r26","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.2090","article-title":"Hospital onset antibiotic resistant infections among patients without COVID-19 diagnosis in pre-pandemic and pandemic periods.","volume":"10","author":"Baggs","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"zoi241727r27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1265","article-title":"The proportion of excess hospital-onset antibiotic-resistant infections attributable to patients diagnosed with COVID-19 in US hospitals, 2019-2021.","volume":"10","author":"Wolford","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"zoi241727r29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1017\/ice.2024.11","article-title":"Implementation of contact precautions for multidrug-resistant organisms in the post-COVID-19 pandemic era: an updated national Emerging Infections Network (EIN) survey.","volume":"45","author":"Howard-Anderson","year":"2024","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"zoi241727r30","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/cid\/ciad388","article-title":"Active Surveillance and contact precautions for preventing methicillin-resistant Staphylococcus aureus healthcare-associated infections during the COVID-19 pandemic.","volume":"77","author":"Evans","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"zoi241727r31","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad503","article-title":"Antibiotic use among hospitalized patients with COVID-19 in the United States, March 2020-June 2022.","volume":"10","author":"Kim","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"zoi241727r32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible staphylococcus aureus bloodstream infections\u2014United States.","volume":"68","author":"Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"zoi241727r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17199","article-title":"Antimicrobial resistance patterns of outpatient staphylococcus aureus isolates.","volume":"7","author":"Carrel","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi241727r34","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/cid\/cix640","article-title":"Trends in methicillin-resistant staphylococcus aureus hospitalizations in the United States, 2010-2014.","volume":"65","author":"Klein","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi241727r35","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab585","article-title":"Methicillin-resistant and methicillin-sensitive Staphylococcus aureus hospitalizations: National Inpatient Sample, 2016-2019.","volume":"9","author":"Klein","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"zoi241727r36","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1017\/ice.2015.202","article-title":"A randomized clinical trial comparing use of rapid molecular testing for staphylococcus aureus for patients with cutaneous abscesses in the emergency department with standard of care.","volume":"36","author":"May","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"zoi241727r37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajem.2008.02.027","article-title":"National epidemiology of cutaneous abscesses: 1996 to 2005.","volume":"27","author":"Taira","year":"2009","journal-title":"Am J Emerg Med"},{"issue":"11","key":"zoi241727r38","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1093\/jac\/dkab269","article-title":"ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18.","volume":"76","author":"Karlowsky","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"zoi241727r39","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/cid\/ciab560","article-title":"Antimicrobial resistance trends in urine Escherichia coli Isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management.","volume":"73","author":"Kaye","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"zoi241727r40","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s10096-019-03655-3","article-title":"Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period.","volume":"38","author":"van Driel","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"zoi241727r41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014.","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"zoi241727r42","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1017\/ice.2017.156","article-title":"Incidence of extended-spectrum \u00df-lactamase (ESBL)-producing Escherichia coli and Klebsiella infections in the United States: a systematic literature review.","volume":"38","author":"McDanel","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"zoi241727r43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/ice.2015.239","article-title":"Increasing incidence of extended-spectrum \u00df-lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States.","volume":"37","author":"Thaden","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"zoi241727r44","doi-asserted-by":"publisher","first-page":"e4552","DOI":"10.1093\/cid\/ciaa1031","article-title":"Antibiotic multidrug resistance of escherichia coli causing device- and procedure-related infections in the United States reported to the National Healthcare Safety Network, 2013-2017.","volume":"73","author":"Kourtis","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"zoi241727r45","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1128\/AAC.02824-14","article-title":"A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.","volume":"58","author":"Banerjee","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"zoi241727r46","doi-asserted-by":"publisher","first-page":"e00377","DOI":"10.1128\/mBio.00377-13","article-title":"The epidemic of extended-spectrum-\u00df-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx.","volume":"4","author":"Price","year":"2013","journal-title":"mBio"},{"issue":"11","key":"zoi241727r47","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1017\/ice.2021.496","article-title":"Epidemiology of extended-spectrum \u00df-lactamase-producing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017.","volume":"43","author":"Duffy","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"zoi241727r48","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1128\/JCM.00346-13","article-title":"Prevalence and characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-producing E. coli isolates in Copenhagen, Denmark.","volume":"51","author":"Olesen","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"3","key":"zoi241727r49","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1086\/653932","article-title":"Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.","volume":"51","author":"Johnson","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi241727r50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/jac\/dkaa399","article-title":"The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community.","volume":"76","author":"Bezabih","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"zoi241727r51","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1017\/ice.2023.76","article-title":"Risk-factor analysis for extended-spectrum beta-lactamase-producing Enterobacterales colonization or infection: evaluation of a novel approach to assess local prevalence as a risk factor.","volume":"44","author":"Cherian","year":"2023","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"zoi241727r52","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"zoi241727r53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"10","key":"zoi241727r54","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1093\/jac\/dkw242","article-title":"Rise and fall of KPC-producing Klebsiella pneumoniae in New York City.","volume":"71","author":"Abdallah","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"zoi241727r55","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad609","article-title":"Trends in incidence of carbapenem-resistant Enterobacterales in 7 US Sites, 2016-2020.","volume":"10","author":"Duffy","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"zoi241727r56","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1093\/jac\/dky322","article-title":"Carbapenemases in New York City: the continued decline of KPC-producing Klebsiella pneumoniae, but a new threat emerges.","volume":"73","author":"Iregui","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"zoi241727r57","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1017\/ice.2018.259","article-title":"Epidemiology of Staphylococcus aureus infections in patients admitted to freestanding pediatric hospitals, 2009-2016.","volume":"39","author":"Spaulding","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"zoi241727r58","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1017\/ice.2020.72","article-title":"Trends in methicillin-resistant Staphylococcus aureus bloodstream infections using statewide population-based surveillance and hospital discharge data, Connecticut, 2010-2018.","volume":"41","author":"Rose","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"zoi241727r59","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1086\/651665","article-title":"Evaluation of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for reporting methicillin-resistant Staphylococcus aureus infections at a hospital in Illinois.","volume":"31","author":"Schaefer","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"zoi241727r60","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/infdis\/jiad028","article-title":"Changes in the incidence of invasive bacterial disease during the COVID-19 pandemic in the United States, 2014-2020.","volume":"227","author":"Prasad","year":"2023","journal-title":"J Infect Dis"},{"issue":"12","key":"zoi241727r62","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1093\/cid\/cix1128","article-title":"Impact of culture-independent diagnostic testing on recovery of enteric bacterial infections.","volume":"66","author":"Imdad","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi241727r65","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae031","article-title":"14-Year Epidemiologic study of Pseudomonas aeruginosa bloodstream infection incidence and resistance in the Veterans Health Administration system, 2009-2022.","volume":"6","author":"Hojat","year":"2024","journal-title":"JAC Antimicrob Resist"},{"issue":"12","key":"zoi241727r67","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S1473-3099(15)00270-4","article-title":"Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study.","volume":"15","author":"Teillant","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"zoi241727r7"},{"key":"zoi241727r14","author":"Izrael"},{"key":"zoi241727r19","author":"Lewis"},{"key":"zoi241727r23"},{"key":"zoi241727r3","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Accessed January 17, 2025. https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/ar-threats-2013-508.pdf"},{"key":"zoi241727r4","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Accessed January 17, 2025. https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/2019-ar-threats-report-508.pdf"},{"key":"zoi241727r5","unstructured":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development, and strategies to prevent and control antimicrobial resistance. World Health Organization. Accessed January 17, 2025. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376776\/9789240093461-eng.pdf?sequence=1"},{"key":"zoi241727r12","unstructured":"Antimicrobial Use and Resistance (AUR) Module. National Healthcare Safety Network. Accessed January 17, 2025. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/11pscaurcurrent.pdf"},{"key":"zoi241727r13","unstructured":"AHA annual survey database. American Hospital Association. Accessed January 17, 2025. https:\/\/www.ahadata.com\/"},{"key":"zoi241727r28","unstructured":"COVID Data Tracker: COVID-NET Laboratory-confirmed COVID-19 hospitalizations. US Centers for Disease Control and Prevention. Accessed January 17, 2025. https:\/\/covid.cdc.gov\/covid-data-tracker\/#covidnet-hospitalization-network"},{"key":"zoi241727r61","unstructured":"510(k) substantial equivalence determination decision summary. US Food and Drug Administration. Accessed January 17, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k"},{"key":"zoi241727r63","unstructured":"Nucleic acid based tests. Secondary nucleic acid based tests March 28, 2024. US Food and Drug Administration. Accessed January 17, 2025. https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/nucleic-acid-based-tests#microbial"},{"key":"zoi241727r64","unstructured":"Antibiotic resistance and patient safety portal. US Centers for Disease Control and Prevention. Accessed January 17, 2025. https:\/\/arpsp.cdc.gov\/"},{"key":"zoi241727r66","unstructured":"Antimicrobial use and resistance (AUR) options. Centers for Disease Control and Prevention. Accessed January 17, 2025. https:\/\/www.cdc.gov\/nhsn\/psc\/aur\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2831512\/wolford_2025_oi_241727_1741359387.28351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:31:39Z","timestamp":1741951899000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2831512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.62059","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}